Ann Intern Med
Switching to tirzepatide improves quality of life in T2D
Clinical takeaway: For patients with T2D not meeting goals on dulaglutide, switching to tirzepatide may improve both metabolic outcomes and how patients feel day to day—largely driven by greater weight and glycemic effects.
In the 40-week SURPASS-SWITCH trial, adults with type 2 diabetes who switched from dulaglutide to tirzepatide had greater reductions in hemoglobin A1c and weight, along with consistently stronger gains in patient-reported outcomes. Tirzepatide is a dual GIP and GLP-1 receptor agonist, while dulaglutide targets GLP-1 alone. Patients who didn't switch instead escalated to higher-dose dulaglutide.
Across measures of quality of life (QoL), physical function, and self-perception, improvements were greater with tirzepatide, including ability to perform daily activities and weight-related QoL. More patients reported feeling “much more” in control of their diabetes, eating, and weight.
These improvements tracked closely with greater reductions in A1c and body weight, suggesting that improved clinical outcomes—rather than a direct drug-specific emotional effect—likely drove gains in well-being.
“Greater clinical effects may be associated with a greater QoL gain for patients,” the study concluded.
Source: Boye KS, et al. (2026, March 31). Ann Intern Med. Patient-reported outcomes in people with type 2 diabetes escalating dulaglutide or switching to tirzepatide